GW Pharmaceuticals

GW is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, EPIDIOLEX (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC. The Company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury. The Company has additional cannabinoid product candidates in clinical trials for autism and schizophrenia.

Biosig Technologies Inc

Coda Octopus Group

Everbridge

Rent-A-Center

Zynex Inc

Despite May's large losses, these stocks to buy made new 52-week highs. Maybe this is a signal that they will continue to head higher.

7 Stocks to Buy That Are Near 52-Week Highs

Aurora Cannabis

Canopy Growth

Cronos Group

Scotts Miracle-Gro

Several CBD manufacturers, researchers, farmers and retailers have urged the regulatory authority to allow the use of cannabis.

FDA to Hold First Public Hearing on Cannabis: 5 Likely Gainers

CVS Health

There's a lot at stake with a key public hearing later this week that's intended to help the FDA establish regulations for the U.S. hemp CBD industry.

What to Expect From the FDA's CBD Hearing

Tilray Brands

There are plenty of marijuana stocks to buy these days. However, these three could be the only ones really worth it for the long haul.

The Only 3 Marijuana Stocks You Need to Own

HEXO Corp

America's most popular professional sport plans to research the medical buzz surrounding pot.

Hut. Hut. High! The NFL to Consider Marijuana as a Possible Pain Management Tool

Zynerba Pharmaceuticals

The CBD trend is heating up as its multiple uses gain traction and laws enable its use. Here are seven marijuana stocks to buy.

7 Marijuana Stocks to Play the CBD Trend

Does GW Pharmaceuticals PLC (GWPH) have what it takes to be a top stock pick for momentum investors? Let's find out.

GW Pharmaceuticals PLC (GWPH) Is Up 1.6% in One Week: What You Should Know

GW Pharmaceuticals reported surging sales last quarter, but investors ought to be aware of a lot more than that.

Marijuana Stocks: 5 Facts You Need to Know About GW Pharmaceuticals Quarterly Results

This drugmaker's cannabidiol formulation could become more widely used following positive phase 3 trial results in tuberous sclerosis complex.

Marijuana Medicine: GW Pharmaceuticals Market Opportunity Could Double

GW Pharmaceuticals, the British biotech that sells the only FDA-approved drug derived from marijuana plants, released a double dose of good news last night and shares rose 1.5%.

GW's Epidiolex has a strong launch and another successful trial

GW Pharmaceuticals PLC-ADR  opened higher by 8 percent Tuesday after posting positive results from its Phase 3 Epidiolex trial and second-quarter earnings beats.

Analysts Raise Price Targets On GW Pharma's Positive Earnings, Epidiolex Results

GW Pharmaceuticals PLC- ADR 's cannabidiol drug Epidiolex is inching closer to another FDA approval.

GW Pharma's CBD Drug Epidiolex Could Secure Label Expansion Following Positive Trial Results

GW Pharmaceuticals PLC shares  soared 9% in premarket trade Tuesday.

GW Pharma shares soar 9% premarket as Oppenheimer upgrades to outperform

GW Pharmaceuticals PLC (GWPH) CEO Justin Gover on Q1 2019 Results - Earnings Call Transcript

GW Pharmaceuticals PLC GWPH, +2.62% shares rose more than 4% in the extended session Monday after the company reported positive phase-three trial results and narrowing losses.

GW Pharmaceuticals stock rises after earnings

GW stock popped late Monday after the biotech's first-quarter sales beat estimates.

Biotech Stock Pops After Cannabis Medicine Outsells Expectations

GW Pharmaceuticals PLC GWPH, +2.62% said late Monday that it had a positive phase-three trial result for its Epidiolex drug.

GW Pharmaceuticals stock rises 6% after positive CBD drug trial

GW Pharmaceuticals will be releasing its next round of earnings this Monday, May 6.

GW Pharmaceuticals Q2 Earnings Preview

Following the U.S.-commercial launch of Epidolex last November, GW Pharmaceuticals (GWPH) continues to see an uptick from the same.

Can Epidolex Drive GW Pharmaceuticals' (GWPH) Q2 Earnings?

Two marijuana stocks currently have at least $1.8 billion in cash and cash equivalents at their disposal.

These 5 Pot Stocks Have the Most Cash

These $5 billion-plus market cap marijuana stocks may not live up to the hype surrounding them.

3 of the Biggest Pot Stocks Have a Lot to Prove

Amarin Corporation Plc

BioMarin Pharmaceutical

Cellectar BioSciences

Sanofi

The biotechnology space is an exciting one with incredible potential for investors.

5 Biotech Stocks With Near-Term Catalysts Ahead

Aphria

Curaleaf Holdings, Inc.

MedMen Enterprises Inc.

Trulieve Cannabis Corp.

You'll find plenty of growers and dispensary operators among the largest marijuana stocks.

News for GW Pharmaceuticals Stock (GWPH)